According to a BBC News report earlier today, abiraterone acetate has been approved for use by National Health Service (NHS) patients with metastic, castration-resistant prostate cancer (mCRPC) in Northern Ireland. A decision about availability of the drug in Scotland is expected on August 13. Abiraterone is already available to NHS patients in England and in Wales.
Filed under: Management, Treatment | Tagged: abiraterone, access, UK |
THE "NEW" PROSTATE CANCER INFOLINK 
This is good news for men in Northern Ireland, and hopefully the Scottish SMC will follow the rest of the UK. I think the SMC has been negotiating with the manufacturers to get a better deal on price as NICE did when they reconsidered approval for abiraterone.